No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IDYA240621P40000
- 3.80
- +0.80+26.67%
15min DelayClose Jun 18 16:00 ET
3.80High3.68Low
3.68Open3.00Pre Close26 Volume84 Open Interest40.00Strike Price9.58KTurnover172.91%IV2.87%PremiumJun 21, 2024Expiry Date2.73Intrinsic Value100Multiplier1DDays to Expiry1.07Extrinsic Value100Contract SizeAmericanOptions Type-0.7036Delta0.0783Gamma10.65Leverage Ratio-0.4877Theta-0.0013Rho-7.49Eff Leverage0.0088Vega
Intraday
- 5D
- Daily
News
Citi's North America Focus List Updated, Adds: Coca-Cola, Evergy, Etc.
Express News | IDEAYA Biosciences Inc : JP Morgan Raises Target Price to $65 From $55
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $63
Stifel analyst Benjamin Burnett maintains $IDEAYA Biosciences(IDYA.US)$ with a buy rating, and adjusts the target price from $55 to $63.According to TipRanks data, the analyst has a success rate of 35
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $50 to $63
On Jun 04, major Wall Street analysts update their ratings for $IDEAYA Biosciences(IDYA.US)$, with price targets ranging from $50 to $63.J.P. Morgan analyst Anupam Rama maintains with a buy rating.Sti
IDEAYA Biosciences Is Maintained at Buy by Stifel
IDEAYA Biosciences Is Maintained at Buy by Stifel
IDEAYA Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 62% Stifel $55 → $63 Maintains Buy 05/13/2024 18.28% Goldman Sachs $53 → $46 Maintains Buy 05/0
Comments
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
11
2
Despite a high cash burn, the significant 55% annual revenue growth of IDEAYA Biosciences is encouraging. The company's limited cash burn relative to market capitalisation suggests it should be able to fuel growth with minor dilution or borrowing. Cash burn thus shouldn't be a major concern.
$IDEAYA Biosciences(IDYA.US$ IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer![]()
$IDEAYA Biosciences(IDYA.US$ @Alvinnnnnnn89 @AmyNic @Ripper1986
starting to look good from a rookie persoe tive. Thanks in advance.
starting to look good from a rookie persoe tive. Thanks in advance.
2
$IDEAYA Biosciences(IDYA.US$ @AmyNic @Ripper1986 great day. in at 18.3
Thanks to peeps pushing me to be better.
Thanks to peeps pushing me to be better.
3
3
Read more
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.